The BioPharm Brief: Mounjaro, ADCs, and Biosimilars

Aug 28, 07:30 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief looks at a new cardiovascular indication for Mounjaro, a billion-dollar ADC deal, and a potential new biosimilar competitor for Kadcyla.

Share
Subscribe
Next
The BioPharm Brief: New Approval, Trial Halt, and Updated Vaccine
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief